In a rough day for PARP inhibitors in ovarian cancer, GSK’s Zejula didn’t deliver a life extension benefit in the final ...

Topline results were announced from a phase 3 study assessing the immune response following coadministration of Arexvy and Shingrix.

GSK has revised its annual vaccine sales forecast following new guidance on RSV from the CDC. But new evidence offers new ...

GSK (NYSE:GSK) announced Wednesday that its Arexvy vaccine for respiratory syncytial virus (RSV) and its Shingrix vaccine for ...

GSK’s twice-yearly depemokimab reduced asthma attacks by half and cut clinic visits by nearly three-quarters, positioning it ...

The NDA includes a combination of Blenrep with bortezomib plus dexamethasone (BorDex) or pomalidomide plus dexamethasone ...

In 2021, GSK said the factory was likely to close in 2025 when its contract with Sandoz ceased "in the absence of any other ...

GSK Plc’s experimental mRNA flu vaccine showed a positive immune response against two key types of flu viruses in a mid-stage trial.

British drugmaker GSK said on Wednesday its experimental herpes simplex virus (HSV) vaccine candidate failed to meet the main ...

British drugmaker GSK said on Wednesday its respiratory syncytial virus (RSV) vaccine, when given together with its shingles ...